Kawasaki, Ryohei
Sakata, Asuka
Hosoda, Chihiro
Harada, Suguru
Soeda, Tetsuhiro
Nishida, Yukiko
Matsumoto, Naoki
Tatsumi, Kohei
Nogami, Keiji
Yoshimura, Yasushi
Shima, Midori
Funding for this research was provided by:
Chugai Pharmaceutical
Article History
Received: 6 April 2023
Accepted: 5 June 2023
First Online: 28 June 2023
Declarations
:
: The study was conducted after obtaining informed consent, and were approved by the Nara Medical University Ethics Committee and Chugai Ethics Committee.
: No identifiable subject information is provided in the manuscript, figures, and table.
: RK, AS, SH, ST, YN, NM, KT and MS: members of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.RK, SH, TS, YN, NM and YY: employees of Chugai Pharmaceutical Co., Ltd.RK, SH, NM and YY: stock ownership of Chugai Pharmaceutical Co., Ltd.TS, YN, YY and MS: Patents for inventions relating to products of Chugai Pharmaceutical Co., Ltd.AS: speaker’s bureau from CSL Behring.CH: no conflict of interest.KT: grants or research support from Japan Blood Products Organization, The Mother and Child Health Foundation and Novo Nordisk Pharma.KN: grants or research support from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., KM Biologics Co., Ltd., Sanofi, Novo Nordisk Pharma, Bayer and CSL Behring; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., KM Biologics Co., Ltd., Sanofi, Novo Nordisk Pharma, Bayer and CSL Behring.MS: representative of Medicinal Biology of Thrombosis and Hemostasis collaborative research laboratory.; research support from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and CSL Behring.; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd.; speaker’s bureau from Chugai Pharmaceutical Co., Ltd., CSL Behring, Sanofi, Bayer, Novo Nordisk Pharma, Takeda Pharmaceutical Co., Ltd., Pfizer and Fujimoto Seiyaku Corp.